EUCRISA Market Drug Insight and Market Forecast - 2032

EUCRISA Market Drug Insight and Market Forecast − 2032

“EUCRISA Market Drug Insight and Market Forecast – 2032” report provides comprehensive insights about EUCRISA for Atopic Dermatitis (AD) in the seven major markets. A detailed picture of the EUCRISA for atopic dermatitis in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the EUCRISA for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EUCRISA market forecast analysis for atopic dermatitis in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.

Drug Summary

EUCRISA (crisaborole) is a non-steroidal phosphodiesterase-4 (PDE4) inhibitor indicated for the topical treatment of mild-to-moderate AD in patients 2 years of age and older. It is currently available as a 2% ointment. The drug is a small, boron-based molecule with low molecular weight, which allows easier penetration into the skin.

In May 2016, Pfizer entered into a definitive merger agreement under which it acquired Anacor, which was developing crisaborole, for approximately USD 5.2 billion.

In March 2020, the US FDA approved Pfizer’s supplemental new drug application (sNDA) for EUCRISA (crisaborole) ointment, 2%, extending the lower age limit from 24 months down to 3 months in children with mild-to-moderate AD, also known as eczema. However, it was previously approved by the brand name EUCRISA for use in adults and children 2 years of age and older. This supplemental approval made EUCRISA the first and only steroid-free topical prescription medication for mild-to-moderate AD patients as young as 3 months of age. This approval for the expanded indication of EUCRISA was supported by data from a Phase IV open-label clinical study designed to assess the safety of crisaborole ointment in infants aged 3 months to less than 24 months with mild-to-moderate AD, with effectiveness as an exploratory endpoint.

The EMA also approved Staquis (crisaborole) to treat adults and children from 2 years of age with mild to moderate AD, in March 2020.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the EUCRISA description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.

Elaborated details on EUCRISA regulatory milestones and other development activities have been provided in this report.

The report also highlights the EUCRISA research and development activities in atopic dermatitis across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around EUCRISA.

The report contains forecasted sales of for atopic dermatitis till 2032.

Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.

The report also features the SWOT analysis with analyst views for EUCRISA in atopic dermatitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EUCRISA Analytical Perspective by DelveInsight

In-depth EUCRISA Market Assessment

This report provides a detailed market assessment of EUCRISA for atopic dermatitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

EUCRISA Clinical Assessment

The report provides the clinical trials information of EUCRISA for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EUCRISA dominance.

Other emerging products for atopic dermatitis are expected to give tough market competition to EUCRISA and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EUCRISA in atopic dermatitis.

Our in-depth analysis of the forecasted sales data of EUCRISA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EUCRISA in atopic dermatitis.

Key Questions

What is the product type, route of administration and mechanism of action of EUCRISA?

What is the clinical trial status of the study related to EUCRISA in atopic dermatitis and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EUCRISA development?

What are the key designations that have been granted to EUCRISA for atopic dermatitis?

What is the forecasted market scenario of EUCRISA for atopic dermatitis?

What are the forecasted sales of EUCRISA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available and how are these giving competition to EUCRISA for atopic dermatitis?

Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?